Indeed, we found that HNPP, as modeled in haplo-insufficient Pmp22 mice (Pmp22+/-), can be clinically alleviated by pharmacologically targeting mTOR signaling. The gene discussed is PMP22; the disease is hereditary neuropathy with liability to pressure palsies.